Drug reference

Teduglutide

GLP-1 Receptor Agonist · Short bowel syndrome agent

GLP-1 Receptor AgonistShort bowel syndrome agentATC A07XA03

CDSCO approvedSchedule HATC A07XA03

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

Specialist sources indicate use if necessary; no human data available.

FDA category + note

Top interactions

BexaroteneSevereDatabaseDDInter

Mechanism

Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine. GLP-2 impacts the proliferation of epithelial cells lining the GI tract, thereby facilitating intestinal adaptation and enhancing fluid, electrolyte, and micronutrient absorption.

Indications

Short bowel syndrome (initiated under specialist supervision)Short-bowel syndrome

Dosing

Adult: 0.05 mg/kg once daily by subcutaneous injection, administered to alternating quadrants of the abdomen; alternatively the thigh can be used. For optimal injection volume per body weight, consult product literature. Review treatment after 6 months.
Renal adjustment: Use half the daily dose in moderate or severe renal impairment and end-stage renal disease.

Pharmacokinetics

Half-life

1 to 2 h

Metabolism

Catabolized by dipeptidyl peptidase 4, but more slowly than native peptide

Excretion

In the urine

Contraindications

Active or suspected malignancy
History of gastro-intestinal malignancy (in previous 5 years)
Patients with active malignancies

Side effects

Common

AnxietyAppetite decreasedCongestive heart failureCoughDyspnoeaFluid imbalanceGallbladder disordersGastrointestinal discomfortGastrointestinal disordersGastrointestinal stoma complicationHeadacheInfluenza like illnessInsomniaNauseaPancreatitisPeripheral oedemaRespiratory tract infectionVomitingAbdominal painFlu-like symptoms

Serious